HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $43 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BridgeBio Pharma (NASDAQ:BBIO) and maintained a price target of $43.
May 30, 2024 | 10:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BridgeBio Pharma and maintained a price target of $43, indicating continued confidence in the company's growth prospects.
The reiteration of a Buy rating and maintenance of a $43 price target by HC Wainwright & Co. suggests strong confidence in BridgeBio Pharma's future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100